Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2018 16:15 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)

NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
March 20, 2018 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
March 19, 2018 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer,...
March 08, 2018 07:45 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update

Company Preparing for Potential Commercial Launch of AZEDRA® (iobenguane I 131) Ahead of U.S. Food and Drug Administration (FDA) April 30th Action DateEnrollment Complete in Phase 3 Trial for...
March 01, 2018 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
February 15, 2018 16:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
February 05, 2018 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating...
February 01, 2018 16:45 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating...
January 02, 2018 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404

NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating...
December 29, 2017 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma

NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right